Comparisons of Clinical Response With Immunoblot, 13q14, LOH, Apoptosis, and In Vitro Drug Sensitivity Testing Data
| Marker . | Normal . | Low CR (%) . | High CR (%) . | P . |
|---|---|---|---|---|
| Bcl-2 | 42 | 4/20 (20) | 3/22 (14) | .69 |
| Bax | 42 | 5/22 (23) | 2/20 (10) | .41 |
| Bcl-2:Bax | 35 | 0/15 (0) | 7/24 (29) | .03 |
| Mcl-1 | 40 | 7/22 (32) | 0/18 (0) | .01 |
| Bak | 37 | 4/18 (22) | 3/19 (16) | .69 |
| BAG-1 | 37 | 5/33 (15) | 2/4 (50) | .15 |
| Caspase-3 | 38 | 5/26 (19) | 2/12 (17) | 1.00 |
| LOH | 36 | 5/27 (18) | 2/9 (22) | 1.00 |
| Spontaneous apoptosis | 29 | 1/11 (9) | 5/18 (28) | .36 |
| In vitro drug sensitivity | 31 | 1/9 (11) | 5/22 (23) | .64 |
| Marker . | Normal . | Low CR (%) . | High CR (%) . | P . |
|---|---|---|---|---|
| Bcl-2 | 42 | 4/20 (20) | 3/22 (14) | .69 |
| Bax | 42 | 5/22 (23) | 2/20 (10) | .41 |
| Bcl-2:Bax | 35 | 0/15 (0) | 7/24 (29) | .03 |
| Mcl-1 | 40 | 7/22 (32) | 0/18 (0) | .01 |
| Bak | 37 | 4/18 (22) | 3/19 (16) | .69 |
| BAG-1 | 37 | 5/33 (15) | 2/4 (50) | .15 |
| Caspase-3 | 38 | 5/26 (19) | 2/12 (17) | 1.00 |
| LOH | 36 | 5/27 (18) | 2/9 (22) | 1.00 |
| Spontaneous apoptosis | 29 | 1/11 (9) | 5/18 (28) | .36 |
| In vitro drug sensitivity | 31 | 1/9 (11) | 5/22 (23) | .64 |
Laboratory data were compared for the patients who did or did not achieve CR (see Table 1 legend for details). The number of clinical responses was determined using National Cancer Institute-sponsored Working Group guidelines.6 NR includes patients who experienced progression while on therapy.